Please assess the completion status of the following clinical trial:

Trial Title: Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for All Participants:~* HCV-infected~* Currently on treatment for HCV OR plan to begin treatment for HCV at the start of this study~* Platelet count less than 50,000 cells/microl~* Hemoglobin greater than 10 g/dl OR greater than 11 g/dl if peginterferon treatment-naive~* Red blood cells are Rh (D) antigen-positive~* Negative Coombs direct antibody test~Inclusion Criteria for HIV Infected Group:~* HIV-infected~Inclusion Criteria for HIV Uninfected Group:~* HIV-uninfected~Exclusion Criteria:~* Prior treatment with intravenous immunoglobulin (IVIG), anti-D, or other medication for the treatment of thrombocytopenia within 30 days of study entry~* Prior serious reaction to plasma products~* Absence of spleen~* Evidence of thrombotic thrombocytopenic purpura (TTP) OR cause of thrombocytopenia other than HCV infection, HCV treatment, or HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.

Based on this trial design, predict the completion outcome and termination type (if applicable).